RODOS BIOTARGET GMBH has a total of 18 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2004. It filed its patents most often in EPO (European Patent Office), United States and Canada. Its main competitors in its focus markets pharmaceuticals, biotechnology and basic materials chemistry are CLIO INC, MINOVIA THERAPEUTICS LTD and NASTECH PHARM CO.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 7 | |
#2 | United States | 4 | |
#3 | Canada | 2 | |
#4 | WIPO (World Intellectual Property Organization) | 2 | |
#5 | Australia | 1 | |
#6 | China | 1 | |
#7 | Republic of Korea | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Basic materials chemistry | |
#4 | Environmental technology |
# | Name | Total Patents |
---|---|---|
#1 | Furch Marcus | 13 |
#2 | Gieseler Robert | 9 |
#3 | Scolaro Michael J | 8 |
#4 | Gieseler Robert K | 8 |
#5 | Sullivan Sean M | 6 |
#6 | Marquitan Guido | 5 |
#7 | Hozsa Constantin | 4 |
#8 | Schwarz Andreas | 2 |
#9 | Marquitan Guido Dr | 1 |
#10 | Schreiter Thomas | 1 |
Publication | Filing date | Title |
---|---|---|
WO2017017148A1 | Immunotherapies for malignant, neurodegenerative and demyelinating diseases by the use of targeted nanocarriers | |
EP3087974A1 | Targeted nanocarriers for targeted drug delivery of gene therapeutics | |
EP2633755A1 | Organ perfusion system | |
EP1761248A1 | Carbohydrate-derivatized liposomes for targeting cellular carbohydrate recognition domains of ctl/ctld lectins, and intracellular delivery of therapeutically active compounds | |
EP1663315A2 | Targeted lipid-drug formulations for delivery of drugs to myeloid and lymphoid immune cells |